Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Two large medical studies from Denmark presented in December 2024 provide more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness.
These two Danish medical studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many.
Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss.
We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss.
And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
We have written about the Ozempic-NAION side effect drug safety issue several times over the past year-and-a-half, and have repeatedly pointed out that NAION is linked to semaglutide, the active ingredient in the currently available Novo Nordisk semaglutide medicines: Ozempic injection, Wegovy injection, Wegovy tablet, and Rybelsus tablet. Further, we have suggested that all these Novo Nordisk semaglutide medicines should have NAION warnings, such that there would be Ozempic-NAION warnings, Wegovy-NAION warnings, and Wegovy-NAION warnings.
But as of late January 2026, when the “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” was released, none of the drug labels for Novo Nordisk semaglutide medicines included any NAION warnings.
To read more of this article, click below:
Before providing some information about why we suggest Ozempic-NAION warnings should be in the recently released January 2026 drug label for the new tablet or pill version of Ozempic that will be available in the US later this year, we direct you to this February 4, 2026, Novo Nordisk USA announcement, “Novo Nordisk introduces Ozempic® Pill; Available in the US Q2 2026” for some information about that new drug product.
Ozempic-NAION Warnings Information
Here are two earlier articles from our Drug Injury Watch blog that provide support for this suggestion that there should be Ozempic-NAION warnings included in that January 2026 drug label for the new pill version of Ozempic, soon to be available, as well as the current drug label for the already available, and popular, Ozempic injection:
- “Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs” (2/13/2026)
- “Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness” (10/22/2025)
The failure by Novo Nordisk to have Ozempic-NAION warnings available for doctors who prescribe Ozempic — or Rybelsus, or Wegovy — as well as the people who use these popular Novo Nordisk semaglutide medicines is the basis for drug injury lawsuits that have been filed against this pharmaceutical company on behalf of people diagnosed with non-arteritic anterior ischemic optic neuropathy, or NAION.
If you have been diagnosed with NAION while using one of those Novo Nordisk semaglutide medicines or soon thereafter, you may want to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online. It is free, confidential, and there is no obligation.
In the alternative, if you have a possible Wegovy, Rybelsus, or Ozempic NAION drug injury lawsuit that you want evaluated by drug injury attorney Tom Lamb, you can send an email to TJL@LambLawOffice.com or call 910-256-2971.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Rybelsus Pancreatitis Warnings and Rybelsus Drug Injury Lawsuits
- A Rybelsus Blood Clots DVT Case
- Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages